These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15876008)

  • 1. The burden of coronary, cerebrovascular and peripheral arterial disease.
    Bakhai A
    Pharmacoeconomics; 2004; 22 Suppl 4():11-8. PubMed ID: 15876008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atherothrombosis: a major health burden.
    Leys D
    Cerebrovasc Dis; 2001; 11 Suppl 2():1-4. PubMed ID: 11316915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic implications of treating atherothrombotic disease in Australia, from the government perspective.
    Ademi Z; Liew D; Hollingsworth B; Wolfe R; Steg GP; Bhatt DL; Reid CM;
    Clin Ther; 2010 Jan; 32(1):119-32; discussion 106-7. PubMed ID: 20171418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry).
    Krempf M; Parhofer KG; Steg PG; Bhatt DL; Ohman EM; Röther J; Goto S; Pasquet B; Wilson PW;
    Am J Cardiol; 2010 Mar; 105(5):667-71. PubMed ID: 20185014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular locations: results from 1-year outcomes in the Japanese REACH Registry.
    Uchiyama S; Goto S; Matsumoto M; Nagai R; Origasa H; Yamazaki T; Shigematsu H; Shimada K; Yamada N; Bhatt DL; Steg PG; Ikeda Y;
    J Neurol Sci; 2009 Dec; 287(1-2):45-51. PubMed ID: 19815240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study).
    Rothwell PM; Coull AJ; Silver LE; Fairhead JF; Giles MF; Lovelock CE; Redgrave JN; Bull LM; Welch SJ; Cuthbertson FC; Binney LE; Gutnikov SA; Anslow P; Banning AP; Mant D; Mehta Z;
    Lancet; 2005 Nov; 366(9499):1773-83. PubMed ID: 16298214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-bed vascular disease and atherothrombosis: scope of the problem.
    Duvall WL; Vorchheimer DA
    J Thromb Thrombolysis; 2004 Feb; 17(1):51-61. PubMed ID: 15277788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of drugs in peripheral vascular disease and stroke.
    Drummond M; Davies L
    J Cardiovasc Pharmacol; 1994; 23 Suppl 3():S4-7. PubMed ID: 7517476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PACIFIC (Prevention of AtherothrombotiC Incidents Following Ischemic Coronary attack) Registry: Rationale and design of a 2-year study in patients initially hospitalised with acute coronary syndrome in Japan.
    Miyauchi K; Morino Y; Tsukahara K; Origasa H; Daida H;
    Cardiovasc Drugs Ther; 2010 Feb; 24(1):77-83. PubMed ID: 20352313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
    Collins R; Armitage J; Parish S; Sleight P; Peto R;
    Lancet; 2004 Mar; 363(9411):757-67. PubMed ID: 15016485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year costs in patients with a history of or at risk for atherothrombosis in the United States.
    Mahoney EM; Wang K; Cohen DJ; Hirsch AT; Alberts MJ; Eagle K; Mosse F; Jackson JD; Steg PG; Bhatt DL;
    Circ Cardiovasc Qual Outcomes; 2008 Sep; 1(1):38-45. PubMed ID: 20031786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year vascular hospitalisation rates and associated costs in patients at risk of atherothrombosis in France and Germany: highest burden for peripheral arterial disease.
    Smolderen KG; Wang K; de Pouvourville G; Brüggenjürgen B; Röther J; Zeymer U; Parhofer KG; Steg PG; Bhatt DL; Magnuson EA;
    Eur J Vasc Endovasc Surg; 2012 Feb; 43(2):198-207. PubMed ID: 22001145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low rates of preventive practices in patients with peripheral vascular disease.
    Anand SS; Kundi A; Eikelboom J; Yusuf S
    Can J Cardiol; 1999 Nov; 15(11):1259-63. PubMed ID: 10579741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparative medical costs of atherothrombotic disease in European countries.
    Levy E; Gabriel S; Dinet J
    Pharmacoeconomics; 2003; 21(9):651-9. PubMed ID: 12807366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The global impact of noncommunicable diseases: estimates and projections.
    Manton KG
    World Health Stat Q; 1988; 41(3-4):255-66. PubMed ID: 3232413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Swiss Atherothrombosis Survey: a field report on the occurrence of symptomatic and asymptomatic peripheral arterial disease.
    Hayoz D; Bounameaux H; Canova CR
    J Intern Med; 2005 Sep; 258(3):238-43. PubMed ID: 16115297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes.
    Bhatt DL; Peterson ED; Harrington RA; Ou FS; Cannon CP; Gibson CM; Kleiman NS; Brindis RG; Peacock WF; Brener SJ; Menon V; Smith SC; Pollack CV; Gibler WB; Ohman EM; Roe MT;
    Eur Heart J; 2009 May; 30(10):1195-202. PubMed ID: 19339264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of stroke and the evaluation of new therapies.
    Kaste M; Fogelholm R; Rissanen A
    Public Health; 1998 Mar; 112(2):103-12. PubMed ID: 9581452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.
    Bhatt DL; Eagle KA; Ohman EM; Hirsch AT; Goto S; Mahoney EM; Wilson PW; Alberts MJ; D'Agostino R; Liau CS; Mas JL; Röther J; Smith SC; Salette G; Contant CF; Massaro JM; Steg PG;
    JAMA; 2010 Sep; 304(12):1350-7. PubMed ID: 20805624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
    Grover SA; Coupal L; Zowall H
    Hypertension; 2005 Jan; 45(1):92-7. PubMed ID: 15545508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.